AKT1 and neoplasm: Activation of TGF-β/Smads inhibits the expression of cyclin-dependent kinase (CDK) inhibitors in advanced tumor cells and simultaneously activates the PI3K/Akt pathway, thereby preventing FoxO and Smad3 recombination.